Clinical pharmacists' contributions to hematopoietic stem cell transplantation: A systematic review.

AIMS: The goal of the present review was to identify studies that assess how pharmaceutical services contribute to hematopoietic stem cell transplantation (HSCT). METHODS: We conducted a systematic literature review of published studies describing results from clinical services provided by pharmacists working with HSCT, conducted according to PRISMA guidelines ( PROSPERO registration number CRD42017062391). A search strategy was applied within PubMed, CENTRAL, EMBASE, SCOPUS, and LILACS databases in April 2017. Inclusion criteria were observational or experimental studies that addressed the following research question: "What are a clinical pharmacist's main contributions to HSCT?" The quality of selected studies was evaluated using the Downs and Black checklist. RESULTS: We identified 1838 studies, and seven were included in the systematic review. The results indicated that clinical pharmacy is useful during HSCT treatment within both inpatient and outpatient settings. Pharmaceutical contributions identified included management of pharmacotherapy-related problems, participation in discussions with clinical teams, drug reconciliation, patient and team education regarding pharmacotherapy, preparation of guidelines and educational materials, and evaluation of medication adherence. These activities favored the control and prevention of pharmacotherapy-related problems, the maintenance of immunosuppressive serum levels, improvement in patients' clinical and nutritional status, facilitated medication adherence, and provided economic and humanistic gains. CONCLUSIONS: Despite the small number of articles discussing the topic under analysis, the results were unanimous in confirming the positive impact of pharmacists' contributions to clinical practice for HSCT.

Seguridad de los pacientes con tratamiento medicamentoso para el trastorno de humor / Patient safety in drug therapy for mood disorders

Introducción: las reacciones adversas a los medicamentos son indicadores de seguridad del paciente, que pueden causar impactos clínicos y económicos. Objetivo: describir las reacciones adversas a los medicamentos en pacientes con trastorno de humor. Métodos: estudio observacional, descriptivo, transversal y prospectivo con un método de búsqueda activa en farmacovigilancia, en pacientes con trastornos de humor atendidos por el Centro de Atención Psicosocial y Ambulatorio de salud en Alfenas, Brasil, durante el periodo de enero a julio de 2011. Los pacientes fueron invitados a participar y respondieron preguntas realizadas en su domicilio a fin de detectar las reacciones adversas a los medicamentos, las que fueron analizadas en cuanto a la causalidad y a la gravedad. Resultados: del total de 31 pacientes, 23 presentaron 60 reacciones adversas a los medicamentos, de ellas el 41,6 por ciento clasifican como probables y 48,3 por ciento como posibles. Todas fueron consideradas no graves, que varían de una a cinco reacciones adversas por paciente. De los 16 medicamentos diferentes utilizados, solo clorhidrato de bupropión no presentó reacciones adversas. Fueron detectadas al menos dos reacciones adversas medicamentos para el resto de los medicamentos. Conclusión: la búsqueda activa identificó que de cada diez pacientes tratados con medicamentos para el control de los trastornos de humor, siete sufrieron una reacción no grave(AU)

Introduction: adverse drug reactions are indicators of patient safety, which can cause clinical and economic impacts. Objective: to describe the adverse drug reactions in patients with mood disorders. Methods: observational, descriptive, cross-sectional and prospective study, with active search method in pharmacovigilance in patients with mood disorders attended by the Center for Psychosocial Ambulatory Health Care in Brazil from January to July 2011. Patients were invited to participate and answer questions posed in their residences in order to detect the adverse drug reactions and to analyze them in terms of causality and severity. Results: of 31 patients, 23 presented with 60 adverse drug reactions, being 41.6% probable and 48.3 percent possible. All the adverse drug reactions were not considered serious, ranging one to five adverse reaction per patient. Of the 16 different medicines used, only bupropion hydrochloride did not present ADR. At least two adverse drug reactions were detected for each medicine. Conclusion: The active search identified that seven patients out of 10 treated with medicines to control mood disorders, had no serious adverse reaction(AU)